Overview

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event
Details
Lead Sponsor:
Bayer
Treatments:
Interferon beta-1b
Interferon-beta
Interferons